Forminet (Metformin)
Film-coated tablets 500 mg – Oral antidiabetic for type 2 diabetes
Quick Facts about Forminet
Key Takeaways about Forminet
- First-line treatment for type 2 diabetes: Recommended as initial pharmacotherapy by ADA, EASD, WHO, and NICE guidelines alongside lifestyle modifications
- Does not cause hypoglycemia alone: Unlike sulfonylureas or insulin, metformin does not stimulate insulin secretion and therefore rarely causes low blood sugar when used as monotherapy
- Weight-neutral or modest weight loss: Forminet does not promote weight gain and may lead to a modest reduction in body weight, making it especially suitable for overweight patients
- Kidney function must be monitored: Renal function (eGFR) should be assessed before starting and at least annually during treatment; dose adjustment is needed if eGFR falls below 45 mL/min
- GI side effects are common but manageable: Nausea, diarrhea, and abdominal discomfort are frequent initially but typically resolve with gradual dose titration and taking tablets with meals
What Is Forminet and What Is It Used For?
Forminet is a prescription medication containing metformin hydrochloride, classified as a biguanide antidiabetic agent. It is primarily used to treat type 2 diabetes mellitus in adults, particularly when diet and exercise alone fail to achieve adequate blood glucose control. Metformin has been used clinically for over 60 years and remains the most widely prescribed oral antidiabetic drug worldwide.
Metformin, the active ingredient in Forminet, was first described in scientific literature in 1922 and entered clinical use in the 1950s. It is derived from Galega officinalis (French lilac), a plant with a long history in traditional medicine for treating symptoms of diabetes. Today, metformin is included on the World Health Organization's List of Essential Medicines, reflecting its critical importance in global healthcare.
Forminet is indicated for the treatment of type 2 diabetes mellitus, especially in overweight patients, when dietary measures and physical exercise alone are insufficient to control blood glucose levels. It may be used as monotherapy (alone) or in combination with other oral antidiabetic agents or insulin. The medication is available as 500 mg film-coated tablets for oral administration.
The primary mechanism by which Forminet exerts its antidiabetic effect involves three complementary pathways. First, it reduces hepatic glucose production by suppressing gluconeogenesis and glycogenolysis in the liver. Second, it enhances the sensitivity of peripheral tissues, particularly skeletal muscle, to insulin, thereby improving glucose uptake. Third, it delays intestinal absorption of glucose. These mechanisms work together to lower both fasting and postprandial blood glucose levels without stimulating insulin secretion from the pancreatic beta cells.
At the molecular level, metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that plays a central role in regulating glucose and lipid metabolism. AMPK activation leads to increased fatty acid oxidation, decreased lipogenesis, and improved glucose transport into cells. This molecular mechanism also explains some of the additional metabolic benefits observed with metformin use, including modest improvements in lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides.
According to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), metformin is recommended as first-line pharmacological therapy for type 2 diabetes due to its proven efficacy, favorable safety profile, weight neutrality, low risk of hypoglycemia, and very low cost. The landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin reduces the risk of diabetes-related complications and mortality in overweight patients with type 2 diabetes.
What Should You Know Before Taking Forminet?
Before starting Forminet, your doctor will assess your kidney function, liver health, and overall medical condition. Certain medical conditions, particularly severe kidney or liver disease, can increase the risk of a rare but serious complication called lactic acidosis. It is essential to inform your healthcare provider about all medications you are taking and any existing health conditions.
Contraindications
Forminet must not be used in the following situations:
- Hypersensitivity to metformin hydrochloride or any of the excipients in the formulation
- Diabetic ketoacidosis or diabetic precoma – these conditions require insulin therapy
- Severe renal impairment with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
- Acute conditions with potential to alter renal function, such as dehydration, severe infection, or shock
- Conditions causing tissue hypoxia including acute heart failure, respiratory failure, recent myocardial infarction, or circulatory shock
- Hepatic insufficiency – severe liver disease or alcoholic liver disease
- Acute alcohol intoxication or chronic alcohol abuse
- Type 1 diabetes – Forminet is not a substitute for insulin
Warnings and Precautions
Several important warnings and precautions apply when using Forminet. Healthcare providers and patients should be aware of the following considerations to ensure safe and effective treatment.
Lactic acidosis is an extremely rare but serious metabolic complication that can occur due to metformin accumulation. The risk increases with uncontrolled diabetes, prolonged fasting, excessive alcohol intake, hepatic insufficiency, and any condition associated with tissue hypoxia or acute kidney injury. The incidence of lactic acidosis with metformin use is estimated at approximately 3–10 cases per 100,000 patient-years. Symptoms include rapid or labored breathing, abdominal pain, hypothermia, muscle cramps, asthenia, and ultimately cardiovascular collapse. If lactic acidosis is suspected, Forminet should be discontinued immediately and the patient should receive urgent medical care.
Renal function monitoring is essential. The eGFR should be assessed before initiation and at least annually thereafter. In patients with eGFR between 30 and 45 mL/min/1.73 m², the daily dose should not exceed 1000 mg and renal function should be monitored every 3–6 months. Forminet should not be initiated if eGFR is below 30 mL/min/1.73 m².
Iodinated contrast media: Forminet must be discontinued before or at the time of the imaging procedure involving iodinated contrast agents and should not be restarted until at least 48 hours afterward, and only after renal function has been re-evaluated and confirmed as stable. This precaution exists because contrast agents can cause acute kidney injury, which could lead to metformin accumulation and lactic acidosis.
Surgery: Forminet should be discontinued on the day of surgery performed under general, spinal, or epidural anesthesia. Treatment may be resumed no earlier than 48 hours after the procedure or upon resumption of oral nutrition, and only after renal function has been reassessed.
Vitamin B12 deficiency: Long-term use of metformin has been associated with decreased absorption of vitamin B12, which may lead to clinically significant deficiency in some patients. This is estimated to occur in 5–10% of patients on long-term therapy. Regular monitoring of vitamin B12 levels is advisable, particularly in patients with megaloblastic anemia or peripheral neuropathy.
Although very rare, lactic acidosis is a medical emergency. Seek immediate medical attention if you experience unexplained rapid breathing, persistent nausea or vomiting, severe abdominal pain, muscle cramps, unusual fatigue, or confusion while taking Forminet. Risk factors include kidney impairment, dehydration, excessive alcohol use, liver disease, and any condition causing poor oxygen supply to tissues.
Pregnancy and Breastfeeding
Forminet is generally not recommended during pregnancy. Uncontrolled diabetes during pregnancy carries significant risks for both the mother and the fetus, including congenital malformations and perinatal mortality. When pregnancy is planned or confirmed, treatment should be switched to insulin to maintain blood glucose levels as close to normal as possible. However, emerging evidence and some clinical guidelines now support the use of metformin in gestational diabetes when lifestyle modifications are insufficient, particularly in women who decline or cannot use insulin.
Metformin is excreted in human breast milk in small quantities. While no adverse effects on breastfed newborns or infants have been observed in limited studies, a decision should be made whether to discontinue breastfeeding or to discontinue Forminet, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Current guidelines from many professional bodies suggest that metformin is likely compatible with breastfeeding, but individual assessment is recommended.
How Does Forminet Interact with Other Drugs?
Forminet can interact with several types of medications that may either increase or decrease its blood glucose-lowering effect, or increase the risk of adverse reactions. Particularly important are interactions with iodinated contrast agents, alcohol, medications affecting kidney function, and drugs that influence blood glucose levels. Always inform your doctor of all medications you are taking.
Drug interactions with metformin are clinically significant and can be broadly categorized into those that increase the risk of lactic acidosis, those that enhance the hypoglycemic effect, and those that reduce the antidiabetic efficacy. Understanding these interactions is crucial for safe and effective management of type 2 diabetes.
Major Interactions
The following interactions require special caution or may necessitate dosage adjustments:
| Drug / Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Iodinated contrast agents | Increased risk of lactic acidosis | High – Contrast can cause acute kidney injury, leading to metformin accumulation | Stop Forminet before procedure; restart after 48 h if renal function stable |
| Alcohol | Increased risk of lactic acidosis and hypoglycemia | High – Alcohol impairs hepatic gluconeogenesis and potentiates metformin effect | Avoid excessive alcohol consumption; avoid binge drinking |
| Insulin / Sulfonylureas | Enhanced hypoglycemic effect | High – Combination increases risk of hypoglycemia | Monitor blood glucose closely; adjust doses as needed |
| ACE inhibitors | May reduce blood glucose levels | Moderate – Additive glucose-lowering effect | Monitor blood glucose; adjust antidiabetic dose if necessary |
| Loop and thiazide diuretics | Increased risk of lactic acidosis; may impair renal function | Moderate – Dehydration can reduce renal function | Monitor renal function; ensure adequate hydration |
Minor Interactions
Several other medications can influence the effect of Forminet, though these interactions are generally less clinically significant:
| Drug / Class | Effect | Action |
|---|---|---|
| Corticosteroids (systemic, inhaled) | May increase blood glucose levels, reducing metformin efficacy | More frequent glucose monitoring; dose adjustment may be needed |
| Beta-2 agonists (salbutamol, terbutaline) | May increase blood glucose via glycogenolysis stimulation | Monitor blood glucose during concurrent use |
| Oral contraceptives | May slightly elevate blood glucose levels | Monitor glucose; generally no dose change needed |
| Cimetidine | Reduces renal clearance of metformin; increases plasma levels by up to 60% | Consider alternative H2 blocker or dose adjustment |
| NSAIDs (ibuprofen, diclofenac) | May impair renal function, especially in dehydrated patients | Use with caution; monitor renal function |
What Is the Correct Dosage of Forminet?
The dosage of Forminet is individualized based on the patient's blood glucose levels and tolerability. Treatment typically starts with a low dose of 500 mg once or twice daily, taken with meals, and is gradually increased over several weeks to minimize gastrointestinal side effects. The maximum recommended daily dose is 3000 mg, divided into 2–3 doses.
Dosage titration is a key principle in metformin therapy. Starting at a low dose and gradually increasing helps minimize the common gastrointestinal side effects that are most pronounced during the initial weeks of treatment. The tablets should be swallowed whole with a glass of water, taken during or immediately after meals.
Adults
Standard Adult Dosing
Starting dose: 500 mg once or twice daily, taken with meals.
Dose titration: After 10–15 days, the dose may be increased based on blood glucose measurements. A gradual increase reduces gastrointestinal side effects.
Usual maintenance dose: 1500–2000 mg daily, divided into 2–3 doses.
Maximum dose: 3000 mg daily, divided into 3 doses. Doses above 2000 mg daily should be evaluated for benefit versus tolerability.
| Week | Morning | Midday | Evening | Daily Total |
|---|---|---|---|---|
| Week 1–2 | 500 mg | – | – | 500 mg |
| Week 3–4 | 500 mg | – | 500 mg | 1000 mg |
| Week 5–6 | 500 mg | 500 mg | 500 mg | 1500 mg |
| Week 7+ | 1000 mg | 500 mg | 500 mg | 2000 mg |
Children and Adolescents
Pediatric Dosing (10 years and older)
Metformin may be used in children aged 10 years and older as monotherapy or in combination with insulin for type 2 diabetes. The starting dose is typically 500 mg once daily, taken with a meal. After 10–15 days, the dose may be increased to 500 mg twice daily. The maximum recommended dose for children is 2000 mg daily, divided into 2–3 doses. Metformin is not recommended for children under 10 years of age due to limited safety and efficacy data.
Elderly Patients
Dosing in Elderly Patients
Due to the potential for reduced renal function in elderly patients, the dose of Forminet should be adjusted based on renal function assessments. The eGFR should be monitored regularly – at least every 3–6 months in patients over 65 years of age. Starting with a lower dose and titrating slowly is recommended to reduce gastrointestinal side effects and minimize the risk of adverse reactions.
Patients with Renal Impairment
Dose Adjustment by Kidney Function
eGFR 45–59 mL/min: No dose adjustment required at initiation; maximum 2000 mg/day. Consider dose reduction if renal function declines during treatment. Monitor eGFR every 3–6 months.
eGFR 30–44 mL/min: Maximum dose 1000 mg/day. Do not initiate new treatment. Monitor eGFR every 3 months.
eGFR <30 mL/min: Forminet is contraindicated and must be discontinued.
Missed Dose
If you miss a dose of Forminet, take it as soon as you remember, provided it is still close to the usual time. If it is almost time for the next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. Missing an occasional dose is unlikely to significantly affect your blood glucose control, but consistently missed doses may lead to suboptimal glycemic management.
Overdose
Hypoglycemia has not been observed with metformin doses up to 85 g (far exceeding the therapeutic range), although lactic acidosis has occurred in such circumstances. Massive overdose or concomitant risk factors for lactic acidosis may lead to this serious complication. Lactic acidosis is a medical emergency and requires hospital treatment. The most effective method of removing metformin and lactate from the body is hemodialysis. If overdose is suspected, seek immediate medical attention.
If you suspect an overdose of Forminet, contact your local poison control center or emergency services immediately. Symptoms of metformin overdose may include severe nausea, vomiting, diarrhea, abdominal pain, rapid breathing, drowsiness, and hypothermia. Lactic acidosis following overdose is a life-threatening emergency requiring hemodialysis.
What Are the Side Effects of Forminet?
The most common side effects of Forminet are gastrointestinal in nature, including nausea, vomiting, diarrhea, and abdominal pain. These typically occur at the beginning of treatment and often resolve on their own. Serious side effects such as lactic acidosis are extremely rare but require immediate medical attention. Importantly, metformin does not cause hypoglycemia when used as monotherapy.
Like all medicines, Forminet can cause side effects, although not everybody gets them. The frequency of side effects is classified according to the international convention used by the European Medicines Agency (EMA) and the World Health Organization (WHO). The gastrointestinal effects are the most commonly reported and are generally self-limiting, particularly when the dose is titrated gradually and the medication is taken with meals.
Very Common
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain and discomfort
- Loss of appetite (anorexia)
Common
- Metallic taste (dysgeusia)
- Flatulence and bloating
- Abdominal cramps
Uncommon
- Skin reactions: erythema, pruritus, urticaria
- Hepatic enzyme abnormalities or hepatitis (reversible upon discontinuation)
Very Rare
- Lactic acidosis (see warnings section)
- Vitamin B12 malabsorption with decreased serum levels (long-term use)
- Megaloblastic anemia (related to B12 deficiency)
The gastrointestinal side effects of metformin are dose-dependent and typically most pronounced during the first few weeks of treatment. They can be minimized by starting at a low dose, increasing gradually over several weeks, and taking the tablets with or immediately after meals. If gastrointestinal symptoms persist despite these measures, a temporary dose reduction may be warranted.
Long-term use of metformin may lead to decreased absorption of vitamin B12 in approximately 5–10% of patients. This effect appears to be mediated through interference with the calcium-dependent B12-intrinsic factor complex in the terminal ileum. Periodic monitoring of vitamin B12 levels is recommended, particularly in patients with signs or symptoms of peripheral neuropathy or macrocytic anemia. Supplementation may be necessary in affected patients.
Most gastrointestinal side effects are mild and resolve over time. However, contact your healthcare provider if you experience persistent or severe gastrointestinal symptoms, unexplained muscle pain or weakness, unusual fatigue, difficulty breathing, or any signs suggestive of lactic acidosis. If you develop symptoms of B12 deficiency such as numbness or tingling in your hands or feet, seek medical evaluation.
How Should You Store Forminet?
Forminet should be stored below 25°C in the original packaging to protect it from moisture. Keep the medication out of the sight and reach of children. Do not use Forminet after the expiry date stated on the carton and blister pack.
Proper storage of medications is essential to maintain their efficacy and safety throughout the shelf life. Forminet 500 mg film-coated tablets should be stored in a dry place at room temperature, not exceeding 25°C (77°F). Avoid exposing the tablets to excessive heat, direct sunlight, or high humidity, as these conditions may accelerate degradation of the active ingredient.
Keep Forminet in its original blister packaging until use. This protects the tablets from moisture and light, which can affect the stability of metformin hydrochloride. Do not transfer tablets to other containers unless they provide equivalent protection. Do not use any tablets that appear discolored, damaged, or have changed in appearance.
Do not use Forminet after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use, as proper disposal helps protect the environment.
What Does Forminet Contain?
Each Forminet film-coated tablet contains 500 mg of metformin hydrochloride as the active substance, equivalent to approximately 390 mg of metformin base. The tablets also contain pharmaceutical excipients necessary for tablet manufacturing and the film-coating.
The active substance in Forminet is metformin hydrochloride. Each tablet contains 500 mg of metformin hydrochloride, which corresponds to approximately 390 mg of metformin base. Metformin hydrochloride is a white to off-white crystalline compound with the chemical formula C4H11N5·HCl and a molecular weight of 165.63 g/mol.
The excipients (inactive ingredients) typically present in metformin film-coated tablets include:
- Tablet core: Povidone (binder), magnesium stearate (lubricant), corn starch (disintegrant/filler)
- Film coating: Hypromellose (film-forming agent), macrogol/polyethylene glycol (plasticizer), titanium dioxide (opacifier)
The film-coated tablet is white to off-white, round, and biconvex in appearance. The film coating serves to improve swallowability, mask the taste of metformin (which has a bitter flavor), and protect the active ingredient from moisture. Patients with known hypersensitivity to any of the listed excipients should consult their healthcare provider before taking Forminet.
Frequently Asked Questions about Forminet
Forminet contains metformin hydrochloride and is used to treat type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone do not achieve adequate glycemic control. It can be used as monotherapy or in combination with other antidiabetic medications or insulin. Metformin is considered the first-line pharmacological treatment for type 2 diabetes by all major international guidelines including the ADA, EASD, WHO, and NICE.
Forminet works through three complementary mechanisms: it reduces glucose production in the liver (hepatic gluconeogenesis), increases the sensitivity of muscle cells to insulin so they take up more glucose from the blood, and decreases the absorption of glucose from the intestines. Unlike sulfonylureas, metformin does not stimulate insulin secretion from the pancreatic beta cells, which is why it does not cause hypoglycemia when used alone. At a molecular level, metformin activates AMP-activated protein kinase (AMPK), a key enzyme regulating energy metabolism.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These effects are most frequent during the initial weeks of treatment and usually resolve on their own. Taking the medication with or after meals and gradually increasing the dose can significantly reduce these symptoms. A metallic taste in the mouth is also reported commonly. Serious side effects like lactic acidosis are extremely rare, occurring in approximately 3–10 cases per 100,000 patient-years.
Forminet (metformin) does not cause hypoglycemia when used as monotherapy because it does not stimulate insulin secretion. This is one of its major safety advantages compared to other diabetes medications. However, hypoglycemia may occur when Forminet is used in combination with insulin, sulfonylureas (such as glipizide or glyburide), or other insulin-secreting agents. If you take Forminet together with such medications, you should be aware of hypoglycemia symptoms including sweating, trembling, confusion, and dizziness.
Yes. Forminet must be discontinued before or at the time of iodinated contrast media administration for imaging procedures (such as CT scans with contrast). It should not be restarted until at least 48 hours after the procedure and only after renal function has been re-evaluated and found to be stable. This precaution exists because contrast agents can temporarily impair kidney function, which could lead to metformin accumulation and the risk of lactic acidosis. For elective surgery under general anesthesia, Forminet should be stopped on the day of surgery and resumed 48 hours later when oral intake is resumed and renal function is confirmed stable.
Forminet (metformin) is considered weight-neutral or may cause modest weight loss, unlike many other diabetes medications (such as sulfonylureas, thiazolidinediones, or insulin) that tend to promote weight gain. Clinical studies suggest an average weight reduction of 1–2 kg over the first year of treatment. This property makes Forminet particularly suitable for overweight or obese patients with type 2 diabetes. However, Forminet is not approved as a weight-loss medication and should not be used solely for this purpose.
Alcohol should be consumed with caution while taking Forminet. Excessive alcohol intake (acute or chronic) increases the risk of lactic acidosis, particularly in cases of fasting, malnutrition, or hepatic insufficiency. Alcohol also impairs the liver's ability to produce glucose (gluconeogenesis), which can potentiate the blood glucose-lowering effect of metformin and potentially lead to hypoglycemia, especially when combined with other antidiabetic drugs. Moderate, occasional alcohol consumption is generally considered acceptable, but binge drinking should be strictly avoided.
References
- American Diabetes Association. Standards of Medical Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1). Available at: diabetesjournals.org/care
- Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034
- European Medicines Agency (EMA). Metformin hydrochloride – Summary of Product Characteristics. Available at: ema.europa.eu
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865. doi: 10.1016/S0140-6736(98)07037-8
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. Available at: nice.org.uk/guidance/ng28
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Available at: who.int
- DeFronzo RA, et al. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20–29. doi: 10.1016/j.metabol.2015.10.014
- Aroda VR, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. doi: 10.1210/jc.2015-3754
- Inzucchi SE, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675. doi: 10.1001/jama.2014.15298
- Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127.
Editorial Team
Medical Authors
iMedic Medical Editorial Team
Specialists in endocrinology, internal medicine, and clinical pharmacology with documented academic background and clinical experience in diabetes management.
Medical Review
iMedic Medical Review Board
Independent panel of medical experts who review all content according to international guidelines from WHO, EMA, ADA, EASD, and NICE. All medical claims verified against Level 1A evidence.
All content on iMedic is written by medical professionals, reviewed by specialist physicians, and updated regularly to reflect current clinical guidelines and evidence. We follow the GRADE evidence framework and have no commercial funding or pharmaceutical company sponsorship. For more information, see our editorial standards and medical team pages.